e-therapeutics Announces Business Updates and Interim Results
October 31, 2024 09:00 ET
|
e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024
August 30, 2024 08:00 ET
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat was well tolerated and showed no impact on systemic hemodynamics in patients with stable angina and chronic coronary syndrome – – These findings support a direct,...
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
March 25, 2024 08:00 ET
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health
November 09, 2023 08:00 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now...
Patient-Focused Next Generation Home Blood Test for Cardiometabolic Health Now Available to Consumers
August 28, 2023 12:08 ET
|
CardioMetaboliQ LLC
—An alarming 93 percent of US adults have less than optimal cardiometabolic health1 and many are completely unaware of their risk— —New test provides end-to-end cardiometabolic health solution, with...
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
May 17, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
SelectHealth Brings Vida Health Virtual Health Solutions to Members Managing Chronic Conditions
March 14, 2023 11:00 ET
|
SelectHealth
Salt Lake City, Utah, March 14, 2023 (GLOBE NEWSWIRE) -- SelectHealth®, a nonprofit health plan serving more than one million members in Utah, Idaho, and Nevada, is pleased to announce a new...
New Cardiometabolic Health Hub Hosted by Healio
February 23, 2023 08:00 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The experts at Cardiometabolic Health Congress (CMHC) announced today that their media partner Healio will host the Cardiometabolic Health Hub, a...
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
January 09, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...